Innovating Cancer Care, By Design
![Mural Oncology immunotherapy employee sitting at desk smiling and folded hands](https://www.muraloncology.com/wp-content/uploads/bb-plugin/cache/2023_Mural_July11th_644-circle-47e884b927e1c2961d99d2ffbb3041e9-yh7ga46c823o.jpg)
Our Mission
Unlocking the value of immunotherapy for more patients
At Mural Oncology we are leveraging our industry-leading protein engineering platform to reimagine cytokine-based immunotherapies for the treatment of cancer. Our mission is simple: to create novel immunotherapies that can change patients’ lives so they can get back to what matters most: living.
We are
Devoted to advancing the field of cancer science
We leverage our expertise in cytokine biology, immune cell modulation and our unmatched protein engineering capabilities to develop first- and best-in-class immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective.
![Woman using lab equipment in a lab setting studying cancer immunotherapy options](https://www.muraloncology.com/wp-content/uploads/bb-plugin/cache/2023_Mural_July11th_834-1-circle-9998052a1e429bd304d5d23a968c8e84-us0npedr4l2i.jpg)
![Digital scan of a cancerous tumor before immunotherapy](https://www.muraloncology.com/wp-content/uploads/bb-plugin/cache/cancer-tumor2-circle-4b214b0712fd04602501cf72fd780980-ks5gyljnbce1.jpg)
![microscopic scan of a cancerous tumor before immunotherapy](https://www.muraloncology.com/wp-content/uploads/bb-plugin/cache/cancer-tumor-circle-57de7a12b13a621eaf137dc7a8196774-bfzd6tpcjw89.jpg)
Explore
Our Pipeline
We are developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available today.
Nemvaleukin Alfa - IL-2 Variant
Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
Featured
Mural Oncology News
Learn about our latest milestones and achievements.
![Mural Oncology logo over water color themed background](https://www.muraloncology.com/wp-content/uploads/2023/11/Mural-Oncology_Open-Graph-1024x538.jpg)
June 5, 2024
Mural to Present and Host 1×1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
![Mural Oncology logo over water color themed background](https://www.muraloncology.com/wp-content/uploads/2023/11/Mural-Oncology_Open-Graph-1024x538.jpg)
May 23, 2024
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
![](https://www.muraloncology.com/wp-content/uploads/2024/03/Caroline-Loew27-xl-1024x508.jpg)
May 14, 2024
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
Are you inspired to make a difference for people living with cancer?
Bring your passion and talent to help us achieve our mission. Visit our Careers page to learn more about what it's like to be part of Mural Oncology and explore current opportunities to join our team.
![female-mural-employee-smiling female mural employee smiling in office](https://www.muraloncology.com/wp-content/uploads/bb-plugin/cache/female-mural-employee-smiling-circle-f6603c91b6b4fa20440ad4c9829ac5c2-t652opbcqvdr.jpg)
Discover
Our Clinical Trials
Clinical trials are currently underway to explore the safety and efficacy of nemvaleukin alfa, a novel, engineered IL-2 variant immunotherapy, in difficult-to-treat cancers with high unmet need.